{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-005624","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.961735+00:00","generated_at":"2026-06-05T12:03:41.179763+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Monopar names Prof. Rodney Hicks lead investigator for MNPR-101-Zr Phase 1 trial","bullets":["Professor Rodney Hicks to lead MNPR-101-Zr Phase 1 dosimetry trial in advanced cancer patients.","Trial will use Siemens Biograph Vision Quadra total-body PET/CT, one of the most sensitive clinical scanners.","MNPR-101-Zr targets cancers with high unmet need, including pancreatic and triple-negative breast cancer.","Enrollment expected to begin shortly at Melbourne Theranostic Innovation Centre (MTIC)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-005624","json":"https://secwatch.observer/filing/0001437749-24-005624.json","markdown":"https://secwatch.observer/filing/0001437749-24-005624.md","text":"https://secwatch.observer/filing/0001437749-24-005624.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924005624/0001437749-24-005624-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924005624/mnpr20240226_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T12:03:41.179763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}